Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies
about
Clozapine: a review of clinical practice guidelines and prescribing trendsAntiepileptic drugs for Tourette's syndromeSecond-generation antipsychotics for major depressive disorder and dysthymiaSecond-generation antipsychotics for anxiety disordersSecond-generation antipsychotics for obsessive compulsive disorderSecond-generation antipsychotic drugs for anxiety disordersSecond-generation antipsychotic drugs for obsessive compulsive disorderPimozide for tics in Tourette's syndromeSecond-generation antipsychotic drugs for major depressive disorderAtypicality of atypical antipsychotics.Pharmacologic treatment of schizophreniaExperimental treatment of antipsychotic-induced movement disordersPrevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatmentIloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapyLong-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorderThe Relationship between Body Weight Change and Body Constitutions of Traditional Chinese Medicine in Patients with SchizophreniaClinical utility of the risperidone formulations in the management of schizophrenia.Extrapyramidal side-effects of antipsychotics in a randomised trial.Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic settingBDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysisCoverage of atypical antipsychotics among medicare drug plans in the state of washington: changes between 2007 and 2008.A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation.The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.Effectiveness evaluation of a pharmacist-driven monitoring database for tardive dyskinesia.Medication-Induced Tardive Dyskinesia: A Review and Update.First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.Modern antipsychotic drugs: a critical overviewRelapse of tardive dyskinesia due to reduction in clozapine doseSafety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.Pharmacological treatment of bipolar disorder among children and adolescents.A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended eventMaintenance therapies in bipolar disorders.Towards a framework for treatment effectiveness in schizophrenia.Paliperidone: a review of clinical trial data and clinical implications.
P2860
Q21260307-447FCD6A-E2AF-4C6D-A604-A25EF29700C3Q24186745-CB0C49A7-C78C-4A75-90D7-87C695E728D3Q24235667-042AE534-678C-4AE6-91F1-5B84EA2EB824Q24235758-4A828938-1BF5-4D37-9DB3-D322DE24D679Q24235770-C2C4B46B-68AC-4553-ACBB-0FD9FAE14419Q24240919-2661D785-BA2F-40AC-926F-112EC862FA2CQ24241138-59655120-A583-4870-BD6B-DBC874022150Q24241313-35E7D629-A36F-4741-8A6F-05976064A7AEQ24241511-FADAB6E7-BCEF-47E8-A341-E012AA81C5ECQ24535908-3B5FEEAC-3EFE-4ADE-B8F3-B0089108545AQ24604457-0B974821-AD83-4865-A16D-BD3531196382Q26740354-0D714674-57A6-4E0E-99D4-66E4FB6DC995Q27028197-226DB856-8FCA-4AE8-9ED4-56E71752ABCEQ28078158-CCA3E0D7-1A84-4264-A470-8301110D5177Q28477329-9B98A846-2447-4B9B-9921-11CCA521670AQ30370448-E3A90DA2-BF21-4550-B648-043E75347297Q30429721-DE7A3F2C-E332-440C-8F8E-931EDBA15C7AQ30492645-F09A9C0E-5FAF-49D4-A8A0-714ED93D1A82Q30590794-96CCCE60-2FA2-4E1F-BE98-8EB0F823CB05Q30747608-8737A5B4-769C-461C-8AAF-FA04849C5759Q33223628-2B9B0EF8-E926-4890-B41B-0021A0F842A3Q33235110-C852A489-AA29-4971-AD58-8C7BC043ED1FQ33435703-1C46204B-1A97-4C30-8A75-6076073B3622Q33566832-5314FBA9-89C5-4863-B7F8-2A3B9DDDB9D1Q33587010-D2367FEB-4CE9-4DC5-B035-1E6316869717Q33699874-09A17FD8-027E-4D7D-BB9D-6708ADE67A60Q33770747-8C244C61-D083-4742-9643-5BC5C89411A5Q33774764-940F24F2-E415-42A2-A0BC-8128A958E01FQ33802645-BD0C9607-3E18-44C7-A208-C24D515623FEQ33845881-69421A36-5398-44F1-BC54-320329FE380AQ33853390-49B21181-8E5D-44C4-A097-EB36990542EBQ33874073-86352EFC-BF27-4F5F-A1CE-84170A43B925Q33878816-239DCB2F-84A5-4D99-8355-79510B0E3094Q34112026-124FDEF2-8487-4D84-9F79-30FBDA21AF41Q34158663-67C08C17-B203-4E39-8471-B0B6341B993DQ34183522-DA523613-7723-41D0-A3CE-000DE28913A1Q34254787-56ED7743-74B4-4148-BC39-028CEFF6EB85Q34268760-FD06F897-C4FE-4677-815C-EFF5306E28B6Q34274631-74498186-74CB-48D2-AE1E-69A19E0A9461Q34321924-CF7115D1-343E-4610-82E4-38F8076EA5A7
P2860
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Lower risk for tardive dyskine ...... matic review of 1-year studies
@ast
Lower risk for tardive dyskine ...... matic review of 1-year studies
@en
Lower risk for tardive dyskine ...... matic review of 1-year studies
@nl
type
label
Lower risk for tardive dyskine ...... matic review of 1-year studies
@ast
Lower risk for tardive dyskine ...... matic review of 1-year studies
@en
Lower risk for tardive dyskine ...... matic review of 1-year studies
@nl
prefLabel
Lower risk for tardive dyskine ...... matic review of 1-year studies
@ast
Lower risk for tardive dyskine ...... matic review of 1-year studies
@en
Lower risk for tardive dyskine ...... matic review of 1-year studies
@nl
P3181
P1476
Lower risk for tardive dyskine ...... matic review of 1-year studies
@en
P2093
Christoph U Correll
John M Kane
P304
P3181
P356
10.1176/APPI.AJP.161.3.414
P407
P577
2004-03-01T00:00:00Z